Andrew K. Balo, EVP, Reg. Strategy, Clinical at DEXCOM INC (DXCM), sold 10,000 shares at $125.24 ($1.2M) on 2018-10-12, disclosed to the SEC on 2018-10-16.
Seasonal sale ($1.2M) by EVP, Reg. Strategy, Clinical — this insider has traded DXCM in October in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $124.49 | 2,991 | $372K | 29.8% |
| 2 | $124.49 | 2,991 | $372K | 29.8% |
| 3 | $125.24 | 2,009 | $252K | 20.2% |
| 4 | $125.24 | 2,009 | $252K | 20.2% |
| Total | $124.79 avg | 10,000 | $1.2M | 100% |
| Filing → |
| DXCM | SELL | 2021-07-08 | $2.4M | — | Filing → |
| DXCM | SELL | 2021-06-07 | $897K | — | Filing → |
| DXCM | SELL | 2021-03-12 | $4.0M | — | Filing → |